{"_id": "65013a93fddc0bb1312fb039", "booleanRepresentation": "{\n    \"$and\":[\n        {\n            \"$and\": [\n                {\"over 70 years of age\"},\n                {\"consultation with the Medical Monitor\"}\n            ]\n        },\n        {\"historically or pathologically confirmed diagnosis of metastatic Stage IV NSCLC without EGFR, ALK, or ROS genomic alterations\"},\n        {\n            \"$or\": [\n                {\"1 additional line of therapy with appropriate targeted therapy for patients with actionable mutations (other than EGFR, ALK, or ROS genomic alterations)\"},\n                {\n                    \"$and\": [\n                        {\"documented radiographic disease progression on or after first-line therapy\"},\n                        {\n                            \"$or\": [\n                                {\"concurrent or sequential ICI and platinum-based chemotherapy \u00b1 bevacizumab\"},\n                                {\"no more than 1 prior line if ICI and platinum-based chemotherapy were administered concurrently\"},\n                                {\"no more than 2 prior lines for sequential administration of platinum-based chemotherapy and ICI as 2 separate lines\"}\n                            ]\n                        }\n                    ]\n                },\n                {\n                    \"$and\": [\n                        {\"LN-145 manufacture allowed for patients with residual resectable disease after completion of platinum-based chemotherapy component of front-line ICI and platinum-based chemotherapy combination\"},\n                        {\"meet all eligibility criteria except documented disease progression\"},\n                        {\"intend to receive TIL therapy after disease progression\"}\n                    ]\n                },\n                {\n                    \"$and\": [\n                        {\"prior systemic therapy in adjuvant or neoadjuvant setting, or as part of definitive chemoradiotherapy\"},\n                        {\"count as a line of therapy if patient had disease progression during or within 12 months after completion of such therapy\"}\n                    ]\n                },\n                {\"at least 1 resectable lesion for TIL production\"},\n                {\"at least one remaining measurable lesion as defined by RECIST v1.1\"},\n                {\"adequate organ function\"},\n                {\"LVEF > 45%, NYHA Class 1\"},\n                {\"adequate pulmonary function\"},\n                {\"ECOG performance status of 0 or 1\"},\n                {\n                    \"$and\": [\n                        {\"patients of childbearing potential or those with partners of childbearing potential\"},\n                        {\"willing to practice an approved method of highly effective birth control during treatment and up to 12 months after all protocol-related therapy\"}\n                    ]\n                }\n            ]\n        },\n        {\n            \"$not\": {\n                \"$or\": [\n                    {\"EGFR driver mutation\"},\n                    {\"ALK driver mutation\"},\n                    {\"ROS driver mutation\"},\n                    {\"symptomatic, untreated brain metastases\"},\n                    {\"allogeneic organ transplant or prior cell therapy within the past 20 years\"},\n                    {\"any form of primary immunodeficiency\"},\n                    {\"on systemic steroid therapy \u2265 10 mg/day of prednisone or equivalent\"},\n                    {\"received a live or attenuated vaccination within 28 days prior to the start of treatment\"},\n                    {\"had another primary malignancy within the previous 3 years\"},\n                    {\"participation in another interventional clinical study within 21 days\"}\n                ]\n            }\n        }\n    ]\n}", "nctId": "NCT04614103", "title": "A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer"}